Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| GLYCOMIMETICS INC | 2,747,866 | reported | 04 Dec 2025 | tx 3+1,500,457 |
| Zenas BioPharma, Inc. | 2,209,025 | reported | 07 Oct 2025 | tx 11+1,958,110−11,330,537 |
| Dianthus Therapeutics, Inc. /DE/ | 1,928,503 | reported | 29 Sept 2023 | tx 1+24,670 |
| Apogee Therapeutics, Inc. | 298,647 | reported | 22 Jan 2026 | tx 10+400,411−2,919,868 |
| Cogent Biosciences, Inc. | 44,700 | reported | 04 Jun 2025 | tx 6+245,461 |
| Jade Biosciences, Inc. | 23,017 | reported | 29 Apr 2025 | tx 1+23,017 |
| Viridian Therapeutics, Inc.\DE | 21,000 | reported | 26 Jun 2024 | tx 6+115,000 |
| Spyre Therapeutics, Inc. | 11,323 | reported | 14 May 2024 | tx 5+3,678,993−90,992 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 22 Jan 2026 | SALE | Apogee Therapeutics, Inc. | 1,750,000 | 76.30 USD | |
| 04 Dec 2025 | PURCHASE | GLYCOMIMETICS INC | 1,360,000 | 13.41 USD | |
| 04 Dec 2025 | PURCHASE | GLYCOMIMETICS INC | 131,434 | 13.41 USD | deriv |
| 07 Oct 2025 | PURCHASE | Zenas BioPharma, Inc. | 316,219 | 19.00 USD | first after silence |
| 23 Jun 2025 | GRANT_AWARD | GLYCOMIMETICS INC | 9,023 | 0.00 USD | deriv |
| 04 Jun 2025 | GRANT_AWARD | Cogent Biosciences, Inc. | 44,700 | 0.00 USD | deriv |
| 29 Apr 2025 | GRANT_AWARD | Jade Biosciences, Inc. | 23,017 | 0.00 USD | deriv |
| 16 Sept 2024 | CONVERSION | Zenas BioPharma, Inc. | 301,077 | — | |
| 16 Sept 2024 | PURCHASE | Zenas BioPharma, Inc. | 300,000 | 17.00 USD | |
| 16 Sept 2024 | CONVERSION | Zenas BioPharma, Inc. | 709,794 | — | |
| 16 Sept 2024 | CONVERSION | Zenas BioPharma, Inc. | 252,890 | — | |
| 16 Sept 2024 | CONVERSION | Zenas BioPharma, Inc. | 41,130 | — | |
| 16 Sept 2024 | CONVERSION | Zenas BioPharma, Inc. | 2,195,871 | — | deriv |
| 16 Sept 2024 | CONVERSION | Zenas BioPharma, Inc. | 6,163,236 | — | deriv |
| 16 Sept 2024 | CONVERSION | Zenas BioPharma, Inc. | 2,614,287 | — | deriv |
| 12 Sept 2024 | GRANT_AWARD | Zenas BioPharma, Inc. | 37,000 | 0.00 USD | deriv |
| 16 Sept 2024 | CONVERSION | Zenas BioPharma, Inc. | 357,143 | — | deriv |
| 26 Jun 2024 | GRANT_AWARD | Viridian Therapeutics, Inc.\DE | 21,000 | 0.00 USD | deriv |
| 05 Jun 2024 | GRANT_AWARD | Cogent Biosciences, Inc. | 44,700 | 0.00 USD | deriv |
| 05 Jun 2024 | GRANT_AWARD | Apogee Therapeutics, Inc. | 10,370 | 0.00 USD | deriv |
| 05 Jun 2024 | GRANT_AWARD | Apogee Therapeutics, Inc. | 10,370 | 0.00 USD | deriv |
| 14 May 2024 | GRANT_AWARD | Spyre Therapeutics, Inc. | 11,323 | 0.00 USD | deriv |
| 14 May 2024 | GRANT_AWARD | Spyre Therapeutics, Inc. | 11,323 | 0.00 USD | deriv |
| 25 Apr 2024 | EXERCISE | Spyre Therapeutics, Inc. | 3,639,680 | 0.00 USD | |
| 25 Apr 2024 | EXERCISE | Spyre Therapeutics, Inc. | 90,992 | 0.00 USD | deriv |
1 purchase reported after at least 12 months of silence — most recent on 07 Oct 2025.